This metabolic phenotype, which is present irrespective of the expression of PGC1α, renders BRAF inhibitor–resistant melanoma cells highly vulnerable to several mitochondrial-targeted compounds including the mitochondrial pro-oxidative drug, elesclomol. The gene discussed is PPARGC1A; the disease is melanoma.